Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunic (IMUX)
NASDAQ:IMUX
Holding IMUX?
Track your performance easily
IMUX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.97 - $2.11
Previous Close$1.11
Volume783.41K
Average Volume (3M)775.27K
Market Cap
$99.99M
Enterprise Value$41.10M
Total Cash (Recent Filing)$59.07M
Total Debt (Recent Filing)$186.00K
Price to Earnings (P/E)―
Beta2.52
Next Earnings
Feb 20, 2025EPS Estimate
-$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding90,079,016
10 Day Avg. Volume1,051,647
30 Day Avg. Volume775,274
Standard Deviation0.24
R-Squared0.17
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)2.33
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.44
Forecast
1Y Price Target
$13.80Price Target Upside1154.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Immunic News
PremiumCompany Announcements
Immunic, Inc. Advances MS Trials Amid Financial Update
PremiumPre-Earnings
Is IMUX a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe interim analysis of their Phase 3 ENSURE trial for vidofludimus calcium in relapsing multiple sclerosis cleared futility with no up-sizing recommended.
Drug DevelopmentThe development of VidoCa continues on track, with Phase 2 data from the CALLIPER trial expected to be a major value-inflecting catalyst.
Market PositioningAnalyst's recommendation reiterates a Buy rating on Immunic, Inc. after conference updates, pointing to materially improved competitive positioning of vidofludimus calcium among its peer late-stage MS therapeutics.
Bears Say
Clinical Study ProspectsThe Phase 3 ENSURE study in RMS is seen as a lower risk, smaller reward opportunity.
Drug Safety ConcernsOutstanding questions on tolebrutinib's liver toxicity remain, with few details provided in the presentation.
Market CompetitionThe opportunity in relapsing multiple sclerosis is seen as having a more crowded commercial landscape, which may limit potential upside.
---
Ownership Overview
9.12% Insiders
5.18% Mutual Funds
42.43% Other Institutional Investors
38.13% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMUX FAQ
What was Immunic’s price range in the past 12 months?
Immunic lowest stock price was $0.97 and its highest was $2.11 in the past 12 months.
What is Immunic’s market cap?
Currently, no data Available
When is Immunic’s upcoming earnings report date?
Immunic’s upcoming earnings report date is Feb 20, 2025 which is in 89 days.
How were Immunic’s earnings last quarter?
Immunic released its earnings results on Nov 07, 2024. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.218 by -$0.022.
Is Immunic overvalued?
According to Wall Street analysts Immunic’s price is currently Undervalued.
Does Immunic pay dividends?
Immunic does not currently pay dividends.
What is Immunic’s EPS estimate?
Immunic’s EPS estimate is -$0.23.
How many shares outstanding does Immunic have?
Immunic has 90,079,020 shares outstanding.
What happened to Immunic’s price movement after its last earnings report?
Immunic reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.218. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immunic?
Among the largest hedge funds holding Immunic’s share is Omega Fund Management, LLC. It holds Immunic’s shares valued at 3M.
---
Immunic Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.80 (1154.55% Upside)
$13.80 (1154.55% Upside)
Blogger Sentiment
Bullish
IMUX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 118.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $99.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.22%
12-Months-Change
Fundamentals
Return on Equity
-216.24%
Trailing 12-Months
Asset Growth
-3.31%
Trailing 12-Months
Company Description
Immunic
Immunic, Inc. engages in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.
---
IMUX Company Deck
---
IMUX Earnings Call
Q3 2024
0:00 / 0:00
---
IMUX Stock 12 Month Forecast
Average Price Target
$13.80
▲(1154.55% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Atara Biotherapeutics
―
Corbus Pharmaceuticals
―
Kiniksa Pharmaceuticals
―
Best Analysts Covering IMUX
1 Year
1 Year Success Rate
2/9 ratings generated profit
1 Year Average Return
-20.06%
reiterated a buy rating 9 months ago
Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -20.06% per trade.
---